ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% - Fierce Pharma

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%    Fierce Pharma A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China    CNBC Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer    statnews.com Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China    Yahoo Finance Lung Cancer Patients on Drug From China’s Akeso Lived Longer    Bloomberg.com

Original source: Google News IR